Cell-based therapy has become a prospective therapeutic strategy for many diseases and has been widely applied in the research of autoimmune diseases. Focusing on cell-based therapy strategies for several years, Creative Biolabs has established advanced platforms with facilities and the latest technologies. With excellent experts specialized in cell-based therapy research, we are capable of providing high-quality cell-based therapy development services for autoimmune disease.
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) capable of initiating and modulating antigen-specific immune responses. They link innate and adaptive immune systems and orchestrate the response of distinct cell types. The patrol and reply skills of DCs consist in antigen sampling and processing, maturation upon encountering potentially harmful agents, and migration to secondary lymphoid organs, particularly to T cell zones, where DCs control the fate of T cells through three main signals:
Due to their critical role in regulating adaptive immune responses and their involvement in various autoimmune disorders, DCs have become an attractive target of immunotherapy.
Thirty years ago, Sakaguchi first confirmed that the CD4+CD25+ T cell subgroups named the regulatory T cells (Tregs), have an immunosuppressive function. Tregs are cells that facilitate the body's immune tolerance to autologous components and maintain immune homeostasis. Reducing the number and function of Treg cells leads to defects of autoimmune tolerance and abnormal immune responses to self-antigens, thus resulting in autoimmune diseases. It has been shown that Tregs are involved in the pathogenesis of many autoimmune diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ANCA-associated vasculitis, etc. Given that Tregs are powerful immunosuppressive agents, immunologists and clinicians hope to treat autoimmune diseases by infusing Tregs in vivo after their isolation and potential amplification ex vivo. Such cell-transfer approaches show a promising ability to alleviate organ transplant rejection.
Fig.1 Environmental effects on the stability of Treg effects of cytokine. (Tao, 2017)
Over the past 2 decades, the use of stem cells in researches has developed rapidly due to their unique capabilities to self-renew as well as to differentiate into numerous specialized cells in the body. Therefore, more focus has been placed toward using these cells for the treatment of several important diseases, including cancer, leukemia, and autoimmune diseases. Cellular therapies have emerged to reset or rebalance the immune system to deal with autoimmune diseases. Among those, stem cell transplantation following high dose chemotherapy has developed as a promising treatment option for patients with autoimmune diseases responding poorly or refractory to conventional treatments.
Fig.2 Hematopoietic stem cell transplantation in patients with autoimmune disease. (Alexander, 2018)
As an industry-leading biopharmaceutical company, Creative Biolabs has thrown a lot of manpower, materials, and financial resource into the research of cell-based therapy. After step-by-step efforts, we have finally established our platform with excellent scientific staff, advanced facilities, and technologies to stay up-to-date. With all these advantages, we have accomplished hundreds of customer-satisfied projects.
Offering comprehensive cell-based therapy development services including dendritic cells, regular T cells, and stem cells, Creative Biolabs is your worry-free partner. If you are interested in cell-based therapy development for autoimmune or you have any questions about our services, please don't hesitate to contact us for more information.
For Research Use Only | Not For Clinical Use
Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.
Copyright © 2023 Creative Biolabs. All Rights Reserved.